Trial Profile

Double blind randomized phase III study of maintenance Pazopanib versus placebo in NSCLC patients non progressive after first line chemotherapy. MAPPING, an EORTC Lung group study.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 01 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pazopanib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms MAPPING

Most Recent Events

11 Jun 2015 Interim results published in the European Journal of Cancer.
03 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
16 Oct 2013 Accrual to date is 17% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com